La vendita allo scoperto per BioLife Solns dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BioLife Solns. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BioLife Solns (NASDAQ:BLFS) Azioni, Report sulle vendite allo scoperto

BioLife Solns

BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.

BioLife Solutions

BioLife Solutions Inc

Reconciliation of Full Year 2024 Revenue Guidance to Preliminary Unaudited Revenue for Continuing Operations
During the fiscal year ended December 31, 2024, the Company divested its freezer business through the previously disclosed sales of its former subsidiaries Global Cooling, Inc. ("GCI") in April 2024 and Arctic Solutions, Inc. (doing business as Custom Biogenics Systems) ("CBS") in November 2024. The Company also divested its storage business through the previously disclosed sale of its former subsidiary SciSafe, Inc. ("SciSafe") in November 2024. Each of the divested businesses previously qualified as a discontinued operation.
As disclosed in our earnings release of November 12, 2024, our revenue guidance for fiscal year 2024 did not include anticipated results from GCI or CBS for that period. Our revenue guidance for fiscal year 2024 did include anticipated results from SciSafe for fiscal year 2024.
The table below reconciles our preliminary unaudited revenue from continuing operations as disclosed herein, plus preliminary unaudited revenue from the discontinued operations of SciSafe for fiscal year 2024 (through the date of its divestiture), to our previously announced revenue guidance range that included anticipated fiscal year 2024 results from SciSafe.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Product line (amounts in thousands)</td>
<td colspan="1" rowspan="1">
Preliminary unaudited total revenue from continuing operations for fiscal year 2024
(a)
</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">
Preliminary unaudited discontinued operations revenue of SciSafe for fiscal year 2024(1)
(b)
</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">
Preliminary unaudited total revenues of operations for fiscal year 2024
(a) + (b)
</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Previously disclosed fiscal year 2024 revenue guidance range</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Difference $</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Difference %</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cell Processing</td>
<td colspan="1" rowspan="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73,535</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; —</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73,535</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$72,000 - $73,000</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,535 - $535</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2% - 1%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Evo and Thaw</td>
<td colspan="1" rowspan="1">8,719</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">—</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">8,719</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SciSafe</td>
<td colspan="1" rowspan="1">—</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">18,440</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">18,440</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Biostorage services</td>
<td colspan="1" rowspan="1">8,719</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">18,440</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">27,159</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$26,000 - $27,000</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,159 - $159</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">4% - 1%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total</td>
<td colspan="1" rowspan="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 82,254</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18,440</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100,694</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$98,000 - $100,000</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2,694 - $694</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3% - 1%</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(1) Column includes revenue from SciSafe through the date of its divestiture, which will be disclosed in the footnotes of our Form 10-K as a key component of the gain/loss from discontinued operations. This amount does not include revenues from GCI or CBS.</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Earnings

News

Guidance

BLFS

BioLife Solutions Divests Freezer Units; Reports $100.7M Total Revenue For 2024, Exceeding Guidance By 1-3%; $73.5M From Cell Processing, $18.4M From SciSafe, And $8.7M From Biostorage Services Including Evo And Thaw

Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million
Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance
BOTHELL, Wash., Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>)&nbsp;("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter and full year preliminary unaudited revenue from continuing operations.
Roderick de Greef, Chairman and CEO, commented, "2024 was a transformative year for BioLife Solutions, marked by solid execution and strategic clarity. We exceeded the upper end of our previously raised revenue guidance for cell processing, with the fourth quarter representing our fifth consecutive quarter of sequential revenue growth for this platform. The divestiture of our freezer and biostorage businesses further streamlined our operations and sharpened our focus as a leading pure-play enabler in the CGT market, positioning BioLife to meet the demands of this rapidly growing modality."
de Greef continued, "Our biopreservation solutions, embedded in 17 approved therapies, highlight our essential role in enabling lifesaving therapies and we expect that to accelerate as the sector continues to mature. As we look to 2025, the momentum in our core business coupled with our fortified balance sheet positions us to deliver sustainable growth and profitability, expand and deepen customer relationships, and create long-term value for our shareholders. We look forward to providing additional detail regarding our 2024 financial performance and outlook for 2025 on our earnings call in February."
Fourth Quarter and Full Year 2024 Preliminary Unaudited Revenue for Continuing Operations
<ul>
<li>Preliminary and unaudited revenue for continuing operations for the fourth quarter of 2024 was $22.7 million, an increase of 31% from $17.4 million for the fourth quarter of 2023.
<ul>
<li>Cell processing platform revenue was $20.3 million, up $5.5 million, or 37%, over the same period in 2023, and up 7% sequentially over the third quarter of 2024.</li>
<li>Evo and Thaw platform revenue was $2.4 million, a decrease of $0.2 million, or 8%, from the same period in 2023.</li>
</ul>
</li>
<li>Preliminary and unaudited revenue from continuing operations for the full year 2024 was $82.3 million, an increase of 8% from $75.9 million for 2023.
<ul>
<li>Cell processing platform revenue was $73.5 million, up $7.8 million, or 12%, from 2023.</li>
<li>Evo and Thaw platform revenue was $8.7 million, down $1.4 million, or 14%, from 2023.</li>
</ul>
</li>
</ul>

Biotech

General

BioLife Solutions Reports $22.7M Q4 Revenue Up 31%; Cell Processing Platform Up 37%, Evo And Thaw Platform Down 8%; Full Year Revenue At $82.3M, Up 8%; Cell Processing Up 12%, Evo And Thaw Down 14%

Northland Capital Markets analyst Carl Byrnes maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Outperform and raises the price target from $28 to $31.

Price Target

Analyst Ratings

Northland Capital Markets Maintains Outperform on BioLife Solns, Raises Price Target to $31

Benchmark analyst Robert Wasserman reiterates BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and maintains $30 price target.

Reiteration

Benchmark Reiterates Buy on BioLife Solns, Maintains $30 Price Target

Keybanc analyst Paul Knight maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Overweight and raises the price target from $30 to $33.

Keybanc Maintains Overweight on BioLife Solns, Raises Price Target to $33

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated BioLife Solns and provided 12-month price targets. The average target is $29.75, accompanied by a high estimate of $32.00 and a low estimate of $27.00. Marking an increase of 2.59%, the current average surpasses the previous average price target of $29.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731934849_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of BioLife Solns by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Steven Mah</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BioLife Solns. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of BioLife Solns compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for BioLife Solns's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into BioLife Solns's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BLFS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BioLife Solns analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About BioLife Solns</h2>
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
<h3>BioLife Solns: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, BioLife Solns showcased positive performance, achieving a revenue growth rate of 29.69% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: BioLife Solns's net margin excels beyond industry benchmarks, reaching -5.57%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): BioLife Solns's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.53%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): BioLife Solns's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.45%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: BioLife Solns's debt-to-equity ratio is below the industry average at 0.12, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For BioLife Solns's Future

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and lowers the price target from $29 to $27.

HC Wainwright & Co. Maintains Buy on BioLife Solns, Lowers Price Target to $27

Asset Sales

BioLife Solutions Sells Subsidiary, Arctic Solutions, For $6.1M

TD Cowen analyst Steven Mah maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and raises the price target from $28 to $31.

TD Cowen Maintains Buy on BioLife Solns, Raises Price Target to $31

Craig-Hallum analyst Matt Hewitt maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and raises the price target from $30 to $32.

Craig-Hallum Maintains Buy on BioLife Solns, Raises Price Target to $32

BioLife Solutions Sees FY24 Revenue $98M-$100M Vs $110.575M Est.

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 55.56 percent. The company reported quarterly sales of $30.600 million which beat the analyst consensus estimate of $25.537 million by 19.82 percent. This is a 8.19 percent decrease over sales of $33.328 million the same period last year.

Earnings Beats

BioLife Solns Q3 2024 GAAP EPS $(0.04) Beats $(0.09) Estimate, Sales $30.600M Beat $25.537M Estimate

Strategic divestiture heightens focus on proprietary, higher-margin cell processing products
All-cash transaction fortifies balance sheet
BOTHELL, Wash., Nov. 12, 2024 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4300340-1&amp;h=643664006&amp;u=https%3A%2F%2Fwww.biolifesolutions.com%2F&amp;a=BioLife+Solutions">BioLife Solutions</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>)&nbsp;("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage subsidiary SciSafe Holdings, Inc. ("SciSafe") for $73 million in cash. SciSafe generated approximately $10.4 million in revenue for the six months ended June 30, 2024.

BioLife Solutions Announces Sale Of Its SciSafe Biostorage Subsidiary For $73M In Cash

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

In the preceding three months, 4 analysts have released ratings for BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.25, a high estimate of $30.00, and a low estimate of $26.00. Surpassing the previous average price target of $23.00, the current average has increased by 22.83%.
<img src="https://www.benzinga.com/files/images/story/2024/1727697680_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of BioLife Solns's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Carl Byrnes</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Steven Mah</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BioLife Solns. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioLife Solns compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BioLife Solns's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BioLife Solns's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BLFS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BioLife Solns analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About BioLife Solns</h2>
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
<h3>BioLife Solns: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, BioLife Solns faced challenges, resulting in a decline of approximately -3.11% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: BioLife Solns's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -73.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): BioLife Solns's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -6.33%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): BioLife Solns's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.34%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.11, BioLife Solns adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From BioLife Solns Analyst Ratings

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy rating and announces Price Target of $29.

Initiation

HC Wainwright & Co. Initiates Coverage On BioLife Solns with Buy Rating, Announces Price Target of $29

Craig-Hallum analyst Matt Hewitt maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Buy and raises the price target from $23 to $30.

Craig-Hallum Maintains Buy on BioLife Solns, Raises Price Target to $30

Northland Capital Markets analyst Carl Byrnes maintains BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) with a Outperform and raises the price target from $26 to $28.

Northland Capital Markets Maintains Outperform on BioLife Solns, Raises Price Target to $28

Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million

BioLife Solns Raises FY24 Sales Guidance From $95.50M-$100M To $99M-$101M Vs. $105.79m

BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.14) by 64.29 percent. This is a 61.54 percent increase over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $28.328 million which beat the analyst consensus estimate of $23.946 million by 18.30 percent. This is a 3.11 percent decrease over sales of $29.237 million the same period last year.

BioLife Solns Q2 2024 Adj. EPS $(0.05) Beats $(0.14) Estimate, Sales $28.328M Beat $23.946M Estimate

TD Cowen analyst Brendan Smith maintained a Buy rating on BioLife Solutions (BLFS – Research Report) today. The company's shares closed today at $2...

BioLife Solutions (BLFS) Receives a Buy from TD Cowen

In a report released today, Paul Knight from KeyBanc maintained a Buy rating on BioLife Solutions (BLFS – Research Report), with a price target of ...

KeyBanc Sticks to Its Buy Rating for BioLife Solutions (BLFS)

Northland raised the firm's price target on BioLife Solutions (BLFS) to $31 from $28 and keeps an Outperform rating on the shares. With the divesti...

BioLife Solutions price target raised to $31 from $28 at Northland

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on BioLife Solutions (BLFS – Research Report), with a pri...

Northland Securities Remains a Buy on BioLife Solutions (BLFS)

In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on BioLife Solutions (BLFS – Research Report). The company's shar...

Craig-Hallum Reaffirms Their Buy Rating on BioLife Solutions (BLFS)

An increase of 31% from $17.4M for the fourth quarter of 2023. Published first on TheFly – the ultimate source for real-time, market-moving breakin...

BioLife Solutions sees Q4 revenue $22.7M, consensus $21.55M

An increase of 8% from $75.9M for 2023. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try N...

BioLife Solutions sees FY24 revenue $82.3M, consensus $104.47M

BioLife Solutions Q4 prelim revenue was $22.7M, up 31%

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on BioLife Solutions (BLFS – Research Report), with a price targ...

Lake Street Reaffirms Their Buy Rating on BioLife Solutions (BLFS)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on BioLife Solutions (BLFS – Research Report). The company's shar...

Craig-Hallum Sticks to Their Buy Rating for BioLife Solutions (BLFS)

Small Cap

Press Releases

BioLife Solutions Reports First Quarter 2024 Financial Results

BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver

BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024

BioLife Solutions Reports Second Quarter 2024 Financial Results

BioLife Solutions to Report Third Quarter 2024 Financial Results and Business Update on November 12, 2024

BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary

BioLife Solutions Reports Third Quarter 2024 Financial Results

BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations

RGEN

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

BioLife Solns

Vendite allo scoperto

BioLife Solns (NASDAQ:BLFS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO